Halle-neustadt, Germany
Halle-neustadt, Germany

Time filter

Source Type

Oschatz C.,Karolinska Institutet | Maas C.,Karolinska Institutet | Lecher B.,Mfd diagnostics GmbH | Jansen T.,Karolinska Institutet | And 12 more authors.
Immunity | Year: 2011

Activated mast cells trigger edema in allergic and inflammatory disease. We report a paracrine mechanism by which mast cell-released heparin increases vascular permeability in vivo. Heparin activated the protease factor XII, which initiates bradykinin formation in plasma. Targeting factor XII or kinin B2 receptors abolished heparin-triggered leukocyte-endothelium adhesion and interfered with a mast cell-driven drop in blood pressure in rodents. Intravital laser scanning microscopy and tracer measurements showed heparin-driven fluid extravasation in mouse skin microvessels. Ablation of factor XII or kinin B2 receptors abolished heparin-induced skin edema and protected mice from allergen-activated mast cell-driven leakage. In contrast, heparin and activated mast cells induced excessive edema in mice deficient in the major inhibitor of factor XII, C1 esterase inhibitor. Allergen exposure triggered edema attacks in hereditary angioedema patients, lacking C1 esterase inhibitor. The data indicate that heparin-initiated bradykinin formation plays a fundamental role in mast cell-mediated diseases. © 2011 Elsevier Inc.


Biologicals are one of the most dynamic growing markets in the field of therapeutics. Biosimilars unlike traditional generic pharmaceuticals copy a complex three dimensional structure based on large molecules. Process and product are closely related to each other. In the case of biosimilars, the production process development is one of the most ambitious aspects during development. The challenge to combine new technologies and economical requirements with a predefined product quality implies a specialized organization to develop these kinds of processes. © Springer-Verlag 2014.


Patent
Scil Proteins | Date: 2011-04-20

The invention relates to a method for producing folded prethrombin, wherein inclusion bodies, which contain unfolded prethrombin or a derivative thereof, are solubilized in a solubilization buffer containing at least one chaotropic compound and at least one organic disulfide compound. The invention further relates to methods for producing thrombin and a-thrombin and derivatives thereof. The invention also relates to solutions that contain folded proteins, which can be produced by the methods according to the invention.


Patent
Scil Proteins | Date: 2012-10-12

The present invention relates to the human and murine melanoma inhibitory activity protein-2 (MIA-2) and to the nucleic acids encoding said proteins including a method for producing such proteins by recombinant techniques. The invention also relates to methods for utilizing such proteins for tissue regeneration, tumor treatment including to control the proliferation and differentiation of liver cells in vivo and in vitro. The invention further relates to diagnostic assays including the human and murine antibodies or aptamers and their use in therapy and diagnosis. Further it relates to diagnostic assays applying specific primers for the diagnostic of liver disease.


The present invention relates to fusion proteins in which a pharmaceutically active component is fused to an antibody mimetic. The invention specifically concerns fusion proteins comprising interferons or biologically active muteins thereof and modified hetero-dimeric ubiquitin proteins as specific targeting domain. The invention further relates to these fusion proteins for use in medicine, in particular for use in the treatment of cancer or infectious diseases. The invention is further directed to pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with such fusion proteins, and in combination with cancer therapeutic agents. Moreover, the invention relates to a method for the generation of said fusion proteins.


The present invention concerns a protein mixture comprising at least a first fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence, which effects that the fusion protein upon expression in a bacterium is translocated through the cytoplasmic membrane in an essentially unfolded state and at least a second fusion protein comprising a protein or protein fragment, and an interaction domain and a protein translocation sequence which effects that the fusion protein is translocated through the cytoplasmic membrane upon expression in a bacterium in an essentially folded state, wherein the interaction domain of the first protein can bind to those of the second protein.


Trademark
Scil Proteins | Date: 2014-07-29

Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes; diagnostic and analytical compositions, not for medical or veterinary use; chemical substances for analysis in laboratories, not for medical or veterinary use; biological compositions for laboratories, not for medical or veterinary use; biological compositions for laboratory analysis and diagnostics. Pharmaceutical and veterinary preparations; medical therapeutic agents, biochemical therapeutic agents, except preparations containing theophylline; diagnostic and/or analytical compositions for medical and/or veterinary use; biological and/or chemical compositions for medical and/or veterinary use. Scientific and industrial research in particular in the biochemical, diagnostic or pharmaceutical fields; biochemistry or pharmaceutical laboratory services; scientific and technological services and research; industrial research and analysis; services and research for the identification and further development of biochemical, pharmaceutical or diagnostic products.


The present invention relates to fusion proteins in which a biologically active moiety is linked to a targeting domain. The invention specifically concerns fusion proteins comprising single-chain (sc) TNFalpha monomers as biologically active moiety and a specific targeting domain, preferably fusion proteins comprising at least three scTNFalpha monomers and modified hetero-dimeric ubiquitin proteins with high affinity to target molecules (Affilin molecules). The invention further relates to these fusion proteins for use in medicine, in particular in the treatment of cancer. The invention is further directed to pharmaceutical compositions comprising such fusion proteins in combination with chemotherapeutics agents.


Patent
Scil Proteins | Date: 2012-06-15

The present invention refers to novel dimeric proteins obtained from modified ubiquitin capable of binding targets with high affinity. The novel dimeric binding proteins comprise a combination of amino acid substitutions and at least one insertion of amino acids in one of the monomers. The invention is further directed to the use of said proteins in medical diagnosis or treatment methods.


Loading Scil Proteins collaborators
Loading Scil Proteins collaborators